Merck's experimental pill, enlicitide, has shown remarkable results in a large study, significantly lowering cholesterol levels in individuals at high risk of heart attacks despite taking statins. This breakthrough pill offers a novel approach to cholesterol management, mimicking the effects of injected medicines. If approved by the FDA, enlicitide could revolutionize treatment for millions, providing an easier-to-use alternative to existing methods.
Statins, the current cornerstone of treatment, block cholesterol production in the liver. However, many patients require additional help to meet LDL cholesterol guidelines. In the study, over 2,900 high-risk patients were randomly assigned to take enlicitide or a placebo. Enlicitide users experienced a 60% LDL cholesterol reduction over six months, a significant improvement over other pills that complement statins. The effectiveness persisted for a year, and there were no safety concerns.
Heart disease is a leading cause of death, and high LDL cholesterol is a critical risk factor. While statins are effective, some patients need more aggressive treatment. Enlicitide, taken on an empty stomach, offers a promising solution. It works by targeting PCSK9, a liver protein that hinders cholesterol clearance, similar to injected drugs like PCSK9 inhibitors. However, these injections are less accessible due to cost and administration challenges.
Merck's study provides compelling evidence of enlicitide's efficacy, comparable to PCSK9 inhibitors. However, further research is needed to demonstrate a reduction in heart attacks, strokes, and deaths, a process that typically takes longer than a year. Merck is conducting a larger study with over 14,000 patients to address this.
The AP Health and Science Department, supported by the Howard Hughes Medical Institute and the Robert Wood Johnson Foundation, emphasizes the potential impact of enlicitide. The study's findings could lead to faster FDA approval, offering a new, effective treatment option for those at high risk of cardiovascular events.
